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Abstract There is a large body of scientific evidence that
has been confirmed in randomized controlled trials indicating
a cardioprotective effect for omega-3 fatty acids from fish.
For alpha-linolenic acid (ALA), which is the omega-3 fatty
acid from plants, the relation to cardiovascular health is less
clear. We reviewed the recent literature on dietary ALA
intake, ALA tissue concentrations, and cardiovascular health
in humans. Short-term trials (6–12 weeks) in generally
healthy participants mostly showed no or inconsistent effects
of ALA intake (1.2–3.6 g/d) on blood lipids, low-density
lipoprotein oxidation, lipoprotein(a), and apolipoproteins A-I
and B. Studies of ALA in relation to inflammatory markers
and glucose metabolism yielded conflicting results. With
regard to clinical cardiovascular outcomes, there is observa-
tional evidence for a protective effect against nonfatal
myocardial infarction. However, no protective associations
were observed between ALA status and risk of heart failure,
atrial fibrillation, and sudden death. Findings from long-term
trials of ALA supplementation are awaited to answer the
question whether food-based or higher doses of ALA could
be important for cardiovascular health in cardiac patients and
the general population.
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Introduction
Omega-3 (n-3) fatty acids can be divided into alpha-
linolenic acid (ALA; C18:3n-3) from plant origin, and
eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic
acid (DHA; C22:6n-3) from seafood. Because the human
body lacks the enzymatic capacity to synthesize ALA, it is
essential to obtain it from the diet.
The estimated average ALA intake in the United States
and most European countries is 1.3 to 1.7 g/d [1–3]. The
Institute of Medicine (IOM) of the National Academies
established Dietary Reference Intakes for macronutrients in
2002 [4]. For ALA, the Adequate Intake (AI) was set at
1.6 g/d for men and 1.1 g/d for women [4]. The IOM noted
that intakes of n-3 fatty acids above the AI may confer
additional health benefits, especially with respect to cardio-
vascular health. Many advisory boards consider ALA
intakes greater than 1.5 g/d important for human health [1].
To achieve an adequate ALA intake, food sources such as
flaxseed and flaxseed oil, walnuts and walnut oil, and
canola and soybean oil are recommended.
For EPA and DHA from fish, there is a vast amount of
epidemiologic evidence indicating a cardioprotective effect.
This evidence has been confirmed in randomized controlled
trials [5–8]. For ALA, the relation with cardiovascular
health is less clear. Several large, prospective cohort studies
in the United States have shown inverse associations of
ALA intake with risk of cardiovascular diseases, but other
epidemiologic studies have been inconclusive [9–11]. A
meta-analysis of observational studies showed that increased
intake of ALA might reduce coronary heart disease (CHD)
mortality by 21%, although this was not statistically
significant [11]. In the Lyon Diet Heart Study, a randomized
controlled trial in coronary patients, consumption of a
Mediterranean-type diet that included an additional daily
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intake of roughly 1 g of ALA significantly decreased the
risk of cardiac death and nonfatal myocardial infarction (MI)
by more than 60% [12]. This study, however, was not
specifically designed to assess the effect of ALA supple-
mentation, and many dietary factors differed between the
experimental and control group. Since then, no randomized
controlled trials of ALA and cardiovascular events have
been published. This article summarizes the current litera-
ture (published after 2008) on dietary ALA intake, ALA
tissue levels, and cardiovascular health in humans.
Effect of ALA Supplementation on Cardiovascular
Risk Factors
Several trials have recently been published on the effect of
ALA supplementation on blood lipids, inflammatory markers,
and other indicators of cardiovascular health (Table 1) [13,
14•, 15–17, 18••]. Trials were mostly of relatively short
duration (6–12 weeks) and ALA doses ranged from 1.2 to
3.6 g/d. There was one long-term trial (52 weeks) in which a
high ALA dose of 8.8 g/d was given [18••]. Increased ALA
intake was achieved by means of flaxseed oil [13, 15], ALA-
enriched margarine [14•], or other ALA-enriched foods
[16, 17, 18••].
Kaul et al. [13] studied the effects of low-dose
supplementation (2 g/d, by means of capsules) of flaxseed
oil, fish oil, and hempseed oil in 86 healthy Canadian men
and women about 34 years of age in a 12-week,
randomized, double-blind, placebo-controlled trial. Flaxseed
oil (ALA dose ∼1 g/d) increased plasma ALA by 30% to
40%, had a small nonsignificant effect on plasma EPA (7%–
8%), and no effect on plasma DHA. None of the treatments
affected serum total, low-density lipoprotein (LDL), or high-
Table 1 Overview of randomized controlled trials of increased alpha-linolenic acid intake and cardiovascular risk factors published between
January 2008 and June 2010
Study/year Population Design Outcome for ALA
Kaul et al.
[13]/2008
88 healthy non-smoking
Canadian men and
premenopausal women,
aged 33 y
12-week, double-blind, parallel
randomized controlled trial;
sunflower oil (placebo), flaxseed
oil (∼1 g/d ALA), hempseed
oil (0.3 g/d ALA), or fish oil
(0.6 g/d EPA+DHA)
Plasma ALA levels increased (P<0.05)
after 6 wk; no differences in total
cholesterol, LDL-C, HDL-C, TG,
LDL oxidation, platelet aggregation,
or inflammation markers (CRP, TNF-α)
Egert et al.
[14•]/2009
79 healthy non-smoking
German men and
premenopausal women,
aged 19–45 y
6-week, double-blind, parallel
randomized controlled trial;
ALA (3.4 g/d), EPA (2.2 g/d),
or DHA (2.3 g/d) via enriched
margarines
LDL-ALA levels increased (P<0.05); fasting
serum TG decreased (P<0.05); no
differences in total cholesterol, LDL-C,
or HDL-C
Barceló-Coblijn
et al. [15]/2008
62 American men >40 y
of age
12-week, parallel randomized
controlled trial; different
doses of flax oil, fish oil, and
sunflower oil in capsules;
ALA doses were 1.2 g/d,
2.4 g/d, and 3.6 g/d
2.4 and 3.6 g/d of ALA significantly
increased erythrocyte ALA and EPA
levels; no differences in inflammation
markers (CRP, TNF-α, sVCAM-1),
total cholesterol, TG, or HDL-C
Sioen et al.
[16]/2009
59 healthy Belgian male
prisoners
12-week single-blind study;
diet with 3.2 g/d extra ALA
No effect on waist circumference, weight,
BMI, systolic blood pressure; diastolic
blood pressure decreased and HDL-C
increased in non-smokers
Bloedon et al.
[17]/2008
62 men and post-menopausal
women from Philadelphia,
aged 44–75 y, with
hypercholesterolemia
10-week, blind, parallel randomized
controlled trial with low-fat diet
with extra flaxseed or with wheat
bran (control); ALA dose
of 3.4 g/d
Serum ALA levels increased; LDL-C was
decreased after 5 wk but not after 10 wk;
lipoprotein(a) was decreased and insulin
sensitivity (HOMA index) improved; no
effect on inflammation (IL-6, hs-CRP)
or oxidative stress (ox-LDL, urinary
isoprostane); HDL-C was reduced
Dodin et al.
[18••]/2008
199 Canadian menopausal
women, aged 49–65 y
52-week, blind parallel trial; 40 g/d
flaxseed or wheat germ; ALA
dose of 8.8 g/d
Serum ALA levels increased; modest
effects on apolipoproteins A-I and B;
no effects on LDL electrophoretic
characteristics or markers of
hemostasis and inflammation
ALA alpha-linolenic acid; BMI body mass index; DHA docosahexaenoic acid; EPA eicosapentaenoic acid; HDL-C high-density lipoprotein
cholesterol; HOMA homeostasis model assessment; hs-CRP high-sensitivity C-reactive protein; IL-6 interleukin-6; LDL-C low-density lipoprotein
cholesterol; sVCAM-1 soluble vascular cell adhesion molecule-1; TG triglycerides; TNF tumor necrosis factor
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density lipoprotein (HDL) cholesterol, triglycerides, LDL
oxidation, platelet aggregation, or inflammatory markers [13].
In another randomized trial in 62 healthy men approximately
40 years of age in the United States, participants were
randomized to flax oil (ALA doses of 1.2, 2.4, or 3.6 g/d),
fish oil (0.6 or 1.2 g/d), or sunflower oil for 12 weeks [15].
Increasing doses of flax oil caused elevation of the ALA
content in erythrocyte membranes by 40% to 80%, and also
of EPA (20%–35%), but not of DHA. None of the treatments
altered plasma inflammatory markers (C-reactive protein
[CRP], tumor necrosis factor [TNF]-α, soluble vascular cell
adhesion molecule-1 [sVCAM-1]), plasma total or HDL
cholesterol, or triglycerides [15].
Bloedon et al. [17] enrolled 62 American men and post-
menopausal women aged 44 to 75 years with hypercholes-
terolemia. All participants were on a low-fat, low-cholesterol
diet and subsequently randomized to flax-based or wheat-
based products for 10 weeks. ALA intake in the flaxseed
group was 3.4 g/d higher than in the control group. Flax-
based products improved insulin sensitivity and reduced
plasma LDL cholesterol by 7% to 13% and lipoprotein(a) by
14% compared with wheat-based products. In men, there was
also a decrease in HDL cholesterol. Treatment had no
effect on markers of inflammation (interleukin-6, high-
sensitivity CRP) or oxidative stress (oxidized LDL, urinary
isoprostanes) [17]. The extent to which the observed effects
of the flax-based diet were due to its ALA content or other
components of flax seeds is not clear.
In a single-blind, 12-week field study among 59 healthy
male prisoners (mean age of 42 years) in Belgium, daily
ALA intake was increased from 2.8 to 4.9 g/d by means of
ALA-enriched foods without changing the linoleic acid
content of the diet [16]. All individuals were first on a
regular diet, which was followed by an ALA-rich diet, and
no randomization was applied. EPA and DHA, but not ALA,
were assessed in platelet phospholipids, which showed no
significant changes during ALA intervention. Body weight,
waist circumference, and systolic blood pressure did not
change, and there were no effects of ALA on plasma total
and LDL cholesterol, triglycerides, apolipoproteins A-I and
B, glucose, and CRP. Diastolic blood pressure, however,
significantly decreased by 3 mm Hg [16].
Egert et al. [14•] studied the effects of increased intake
of ALA, EPA, and DHA in a 6-week parallel trial in 74
German normolipidemic men and women aged 19 to
43 years. Participants were randomly assigned to trial
margarines that provided additional ALA (3.4 g/d), EPA
(2.2 g/d), or DHA (2.3 g/d). No placebo group was
included. In the ALA group, the ALA content of LDL
particles increased by 178% and the EPA content increased
by 36%, whereas DHA remained unchanged. Serum total and
LDL cholesterol were not affected by the different treatments.
Fasting serum triglycerides significantly decreased with EPA
(−0.14 mmol/L), DHA (−0.30 mmol/L), and ALA
(−0.17 mmol/L). DHA intake significantly increased serum
HDL cholesterol, whereas no changes were found with ALA
or EPA intake [14•].
Finally, Dodin et al. [18••] evaluated the effect of
flaxseed on markers of cardiovascular disease risk in 169
healthy menopausal Canadian women who were randomly
assigned to 40 g/d of flaxseed-based products or wheat-
based products for 12 months. In the active-treatment
group, ALA intake was increased by 8.8 g/d. Flaxseed
products increased plasma ALA by 85% and plasma EPA
by 51% after 12 months of intake, which differed
significantly from wheat-based intervention (12% and
29%, respectively). Changes in plasma DHA were similar
in both groups. The 12-month intervention with flaxseed
had significant effects on body weight (−0.8 kg) and serum
total cholesterol (−0.20 mmol/L) and a small adverse effect
on HDL cholesterol (−0.08 mmol/L). LDL cholesterol was
reduced by 0.13 mmol/L (P=0.09). Apolipoproteins A-I
and B increased in both groups, but less during flaxseed-
based than wheat-based intervention. Treatment had no
effect on plasma lipoprotein(a), fibrinogen, CRP, insulin,
glucose, or LDL peak particle size. The effect of ALA on
plasma triglycerides was not reported [18••].
Observational Studies on ALA Intake
and Cardiovascular Risk
Zatónski et al. [2] examined trends in CHD mortality in 11
Eastern European countries and linked these figures to
national data on vegetable oil consumption after 1990. They
showed the strongest decline in CHD mortality in countries
where rapeseed oil (9% ALA) rather than sunflower oil (0%
ALA) was used. Although these data are suggestive for a
beneficial effect of ALA, no definite conclusions can be
drawn because the countries also differed in many other
aspects that could impact cardiovascular health. Cross-
country comparisons based on aggregate data cannot be
adjusted for potential confounders, (eg, socioeconomic
status, lifestyle and other dietary components) and should
be considered for hypothesis generation only.
In Costa Rica, soybean oil has been substituted for palm
oil since the 1980s, which has led to an increase in ALA
intake. Campos et al. [19••] performed a case–control study
in 3638 Costa Rican individuals to examine the association
between ALA and nonfatal MI (Fig. 1). Participants were
matched for age, sex, and area of residence. ALA intake
was assessed by a 135-item food frequency questionnaire
and ranged from 1.1 to 2.4 g/d (mean, 1.6 g/d) in this
population. Dietary ALA was inversely associated with
nonfatal MI, with odds ratios indicating a 39% reduced risk
for approximately a 0.6-g/d difference in intake. The
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relationship between ALA and MI was nonlinear and
mainly confined to the lowest levels of intake. Dietary
ALA intake in this study correlated well with ALA in
adipose tissue, plasma, and erythrocytes, but poorly with
biomarkers of EPA and DHA, suggesting a direct cardio-
protective effect of ALA rather than via conversion to long-
chain n-3 fatty acids [19••].
An anti-inflammatory action of ALA has been proposed
as an explanation for the inverse association with cardio-
vascular diseases found in the case–control study in Costa
Rica [19••], although negative findings on ALA and
inflammatory markers have been reported by others [9].
Dai et al. [20•] examined habitual ALA intake and plasma
concentrations of inflammatory markers, including IL-6 and
sIL-6R, in 353 middle-aged men in the United States who
were recruited from a twin registry. ALA intake, assessed
by the Willett questionnaire, ranged from 0.2 to 2 g/d, and
was significantly inversely related to plasma sIL-6R inde-
pendent of shared genetic factors and a wide range of
potential confounders. A twin with a 1-g higher ALA intake
(equivalent to one tablespoon of canola oil) had 11% lower
sIL-6R concentrations than his twin with a low intake.
Despite the robust association with sIL-6R, no significant
associations were found with plasma IL-6, TNF-α, or high-
sensitivity CRP [20•]. In a study of 511 Japanese employees
of municipal offices, ALA intake was assessed by a diet
history questionnaire that had been validated against 16-day
weighed food records (Pearson correlation for ALA, r=0.3)
[21]. ALA comprised 0.8% to 1.0% energy (>2 g/d) and
was inversely related to serum CRP. Data were adjusted for
age, body mass index (BMI), lifestyle factors, and physical
activity, but not for dietary factors associated with ALA,
and should therefore be interpreted with caution.
Smith et al. [22•] assessed dietary ALA intake by the
Willett questionnaire in 260 post-MI patients and linked these
data to 24-hour electrocardiogram recordings that were
analyzed for ventricular premature beats. ALA intake
(expressed per 1,000 kcal/d) was associated with a significant
reduction in ventricular premature beats after adjustment for
age, sex, cardiovascular medication, and co-morbidities.
However, lifestyle (eg, smoking) and dietary factors were
not controlled for and the study had a cross-sectional design,
which has inherent methodologic weaknesses.
Biomarker Studies of ALA and Cardiovascular Risk
Previous analyses in the National Heart, Lung, and Blood
Institute NHLBI Family Heart Study suggested that ALA
may protect against atherosclerosis [23, 24]. Recently, Sala-
Vila et al. [25] investigated whether serum phosphatidyl-
choline content of ALA and other fatty acids was related to
carotid atherosclerosis in a cross-sectional study of 451
asymptomatic Spanish individuals (mean age of 45 years)
with primary dyslipidemia. Over half of the participants
were treated with lipid-lowering drugs. The habitual
Mediterranean diet in this population provided a mean
ALA intake of 0.8 g/d, mainly from olive oil and walnuts,
which correlated well with serum ALA (r=0.44). EPA and
DHA intake from fish was 1.05 g/d on average. The
association of serum fatty acids with intima-media thick-
ness (IMT) of the carotid arteries was assessed, adjusting
for age, sex, BMI, smoking, antihypertensive drugs, statins,
and other serum fatty acids. Significant inverse associations
were found between serum ALA and internal carotid artery
IMT, and between serum DHA and common carotid artery
IMT. Serum EPA was not associated with IMT [25]. In a
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Fig. 1 Odds ratios and 95% confidence intervals for nonfatal
myocardial infarction (MI) by deciles of alpha-linolenic acid in
adipose tissue (a) or intake (b) in a case–control study of 3638 men
and women in Costa Rica. Data were adjusted for smoking status,
physical activity, household income, history of diabetes mellitus,
history of hypertension, waist-to-hip ratio, saturated fat intake, and
linoleic and trans fatty acids in adipose tissue. (From Campos et al.
[19••]; with permission)
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small cross-sectional study of 50 Asian men and women
(mean age of 58 years) who suffered a first nonfatal MI,
the mean common carotid IMT was inversely associated
with ALA content of erythrocytes (P=0.09) and ALA
intake (P=0.02) [26]. Data, however, were only adjusted
for age, sex, and total energy (for dietary ALA). EPA and
DHA were not consistently related to IMT. The average
intake of ALA was 0.6 g/d, which was similar to that of
EPA and DHA intake.
Ebbesson et al. [27] examined whether ALA content of
erythrocytes was related to heart rate as a risk indicator for
ventricular arrhythmias. They performed a cross-sectional
study in 707 Alaskan Eskimos (mean age of 50 years) who
had a habitual intake of marine n-3 fatty acids of 2.9 g/d. After
adjustment for gender, height, BMI, blood pressure, smoking,
and heart rate–lowering medications, no association was
observed with ALA (P=0.98). EPA and DHA, on the other
hand, were significantly inversely associated with heart rate.
The delta(6)-desaturase enzyme is the rate-limiting step
in the conversion of ALA into EPA and DHA, and genetic
variation in the delta(6)-desaturase gene (FADS2) may
therefore affect the associations of ALAwith cardiovascular
health. Truong et al. [28], in a cross-sectional study,
examined the association of ALA in adipose tissue with
metabolic syndrome, and possible effect modification by
FADS2. In a cohort of 1,815 men and women from Costa
Rica, the prevalence of metabolic syndrome (656 cases)
was 19% lower in the upper compared with the lower
quintile of adipose tissue ALA. There was no association
between ALA and metabolic syndrome among homozygous
carriers of the FADS2 deletion allele, suggesting that
conversion of ALA into EPA may play a role [28]. It should
be noted, however, that the FADS2 polymorphism did not
influence the inverse association of ALA with nonfatal MI
in a previous case–control study from Costa Rica [29].
Biomarker Studies of ALA and Cardiovascular
Endpoints
ALA status has been inversely associated with cardiovas-
cular disease events, although data are less consistent than
for EPA and DHA [7–10]. An overview of ALA biomarker
studies is provided in Table 2. In the aforementioned case–
control study by Campos et al. [19••], ALA was measured
in adipose tissue as a biomarker of intake, which correlated
well with dietary ALA. ALA was strongly inversely
associated with nonfatal MI, with a 57% reduced risk when
comparing the 7th decile with the lowest decile. The
relationship between ALA and MI was nonlinear and mainly
confined to levels below the median (Fig. 1). Mozaffarian et
al. [30] suggested that ALA may particularly reduce CHD
risk when intake of marine n-3 fatty acids is low. In the
study by Campos et al. [19••], however, concurrent fish
intake (range, 3–32 g/d) or EPA and DHA intake (range,
130–520 mg/d) did not modify the associations of ALA
with MI.
Yamagishi et al. [31] examined the prospective associ-
ation of plasma fatty acids with risk of heart failure. The
data used were from 3,575 white men and women in the
United States (mean age of 54 years) who participated in
the Atherosclerosis Risk in Communities (ARIC) study.
During 14 years of follow-up, 195 cases of heart failure
developed. Concentrations of n-3 fatty acids were assessed
in plasma cholesteryl esters and in phospholipids. Plasma
ALA was not associated with risk of heart failure (hazard
ratios of 0.99 and 0.97 for upper versus lower quintiles of
cholesteryl ester and phospholipid fractions, respectively;
P=0.8). Plasma EPA also showed no association. Plasma
DHA was inversely associated with incident heart failure,
but only in women. Data were extensively adjusted for major
confounders, including age, sex, BMI, lifestyle factors, and
cardiovascular risk factors, but not for potential dietary
confounders [31].
Warensjö et al. [32] conducted a prospective cohort
study of ALA in serum cholesteryl esters and cardiovascular
mortality in more than 2,000 Swedish men (mean age of
50 years). The study had 30 years of follow-up and
comprised over 60,000 person-years. A 10% higher risk of
fatal cardiovascular events was found per standard deviation
increase in serum ALA, which was borderline statistically
significant. Data were adjusted for serum cholesterol, BMI,
smoking, physical activity, and presence of hypertension.
Erythrocyte concentrations of n-3 fatty acids were
studied in relation to hemorrhagic and ischemic stroke in
a case–control study of 120 Asian men and women (mean
age of 57 years) [33]. The average total n-3 fatty acid intake
in this population was 1.1 g/d, about half of which was
ALA. Erythrocyte ALA concentrations (area%) were 0.71±
0.21 in hemorrhagic stroke patients and 0.24±0.03 in
ischemic stroke patients, which did not differ significantly
from controls (0.44±0.05) after adjustment for family
history of stroke. In a logistic regression model, both
ALA, EPA and DHA were significantly inversely related to
ischemic stroke. EPA and DHA were also inversely related
to hemorrhagic stroke, but this was not the case for ALA.
Data, however, were only adjusted for age and systolic
blood pressure, so residual confounding may have been
present.
The risk of atrial fibrillation in relation to serum n-3 fatty
acids was examined in a prospective cohort study of 2,174
Finnish men (mean age of 53 years) [34••]. During 18 years
of follow-up, 240 events of atrial fibrillation occurred.
Serum ALA was not associated with incidence of atrial
fibrillation. Hazard ratios in consecutive quartiles of ALA
were 1.26 (95% CI, 0.84–1.89), 0.74 (95% CI, 0.46–1.20),
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and 1.14 (95% CI, 0.72–1.79) compared with the lowest
quartile (P for trend = 0.98). Serum EPA did not show an
association but DHA was inversely related to atrial
fibrillation (hazard ratio of 0.62 for upper vs lower quartile;
P for trend = 0.02) [34••].
Finally, Lemaitre et al. [35••] investigated in a case–
control study whether ALA levels in erythrocytes were
associated with risk of sudden cardiac death. Blood was
collected from 265 out-of-hospital sudden cardiac arrest
patients in Seattle, WA immediately after the event and
from 415 randomly selected community members (mean
age of 58 years). In contrast to what was expected, higher
ALA levels were associated with a higher risk of sudden
cardiac arrest. After adjustment for age, sex, smoking,
diabetes, hypertension, education, physical activity, weight,
height, and total fat intake, the risk increased over the
quartiles with an odds ratio of 2.5 (95% CI, 1.3–4.8) for the
highest compared with the lowest quartile. The association
was independent of other fatty acids in erythrocyte
membranes, including EPA and DHA [35••].
Table 2 Overview of biomarker studies of alpha-linolenic acid and cardiovascular events published between January 2008 and June 2010
Study/year Population Design Outcome
Campos et al.
[19••]/2008
Costa Rica: 1,891 cases with
first nonfatal MI and 1,891
population-based controls;
matching for age, sex, and
area of residence
Case–control study: association
of ALA intake from FFQ and
ALA in adipose tissue with
risk of first nonfatal MI
OR (95% CI) for first nonfatal MI was
0.41 (0.25–0.67) for top vs lowest decile
of ALA in adipose tissue, and 0.61
(0.42–0.88) for high vs low ALA
intake; associations only present at
lower ALA levels
Yamagishi et al.
[31]/2008
USA, Minneapolis: 3,575 white
men and women from ARIC
study, ages 45–64 y
Prospective cohort study: association
of plasma ALA with incident heart
failure; 14.3 y of follow-up
195 participants (5.5%) developed heart
failure; ALA status (top vs bottom
quintile) was not associated with
incident heart failure; age- and sex-
adjusted HR was 0.99 (0.63–1.53) for
cholesteryl ester fraction and 0.97
(0.61–1.54) for phospholipid fraction
Warensjö et al.
[32]/2008
Sweden: 2,009 men from
ULSAM study, aged 50 y
Prospective cohort study: association
of ALA in serum cholesteryl esters
with CVD mortality; 30.7 y of
follow-up
Multivariable-adjusted HR was 1.10
(1.00–1.21) per 1-SD increase in
serum ALA
Park et al.
[33]/2009
South Korea: 40 cases of
ischemic stroke, 40 cases
of hemorrhagic stroke and
40 healthy controls;
matching for age and sex
Case–control study: association of
ALA in erythrocytes with risk of
ischemic and hemorrhagic stroke
Erythrocyte ALA concentrations (area%)
in hemorrhagic stroke patients (0.71±
0.21) and ischemic stroke patients
(0.24±0.03) were not significantly
different from controls (0.44±0.05)
after adjustment for family history of
stroke; inverse association of ALA
with ischemic stroke after adjustment
for age and systolic blood pressure
(P=0.045).
Virtanen et al.
[34••]/2009
Finland: 2,174 men from
Kuopio Ischemic Heart
Disease Risk Factor Study,
ages 42–60 y
Prospective cohort study: association
of serum ALA with incident atrial
fibrillation; 17.7 y of follow-up
240 men (11.0%) developed atrial
fibrillation; multivariable-adjusted
HR for serum ALA (compared to Q1)
was Q2: 1.26 (95% CI, 0.84–1.89),
Q3: 0.74 (0.46–1.20), and Q4: 1.14
(0.72–1.79; P for trend = 0.98).
Lemaitre et al.
[35••]/2009
USA, Seattle: 265 out-of-
hospital sudden cardiac
arrest patients and 415
community members;
matching for age, sex,
and calendar year
Case–control study: association of
ALA in erythrocytes with risk of
sudden cardiac death; blood
collection immediately after the
event (patients) or during
interview (control)
Multivariable-adjusted OR over quartiles
of ALA in erythrocytes (compared
to Q1): Q2 was 1.7 (1.0–3.0), Q3
was 1.9 (1.1–3.3), Q4 was 2.5 (95%
CI, 1.3–4.8); association independent
of erythrocyte levels of EPA and
DHA, linoleic acid, and trans fatty
acids
ALA alpha-linolenic acid; ARIC Atherosclerosis Risk in Communities; CVD cardiovascular diseases; DHA docosahexaenoic acid; EPA
eicosapentaenoic acid; FFQ food frequency questionnaire; HR hazard ratio; MI myocardial infarction; OR odds ratio; Q quartile; SD standard
deviation; ULSAM Uppsala Longitudinal Study of Adult Men
Curr Atheroscler Rep
Conclusions
The trials reviewed here consistently showed an increase in
blood ALA levels after ALA supplementation, starting at
low doses (<2 g/d). ALA supplementation also increased
blood levels of EPA, but not of DHA, indicating conversion
of ALA to EPA through elongation and desaturation. Short-
term trials (6–12 weeks) in generally healthy individuals
mostly showed no or inconsistent effects of ALA intake
(1.2–3.6 g/d) on blood lipids, LDL oxidation, lipoprotein
(a), and apolipoproteins A-I and B. Previous studies
suggested an anti-inflammatory action of ALA [5, 7, 8],
but recent trials showed little effect of ALA on CRP or
other inflammatory markers. There was, however, an
interesting inverse association of ALA with sIL-6R in the
twin study by Dai et al. [20•], which warrants further
investigation. The few studies that addressed ALA intake in
relation to glucose metabolism or blood pressure yielded
inconsistent results [16, 17, 18••]. There is, however, some
observational evidence that a high ALA status may be
related to a lower risk of metabolic syndrome [28]. Long-
term treatment with high ALA doses had a beneficial effect
on body weight and blood LDL cholesterol [18••], which
warrants confirmation in future trials.
Previous evidence favored recommendations for modest
dietary consumption of ALA (2–3 g/d) for the primary and
secondary prevention of CHD [7]. The recently published
case–control study by Campos et al. [19••] showing strong
inverse associations of ALA status and intake with nonfatal
MI is in line with this recommendation. Recent data
provide some support that ALA could protect against
atherosclerosis [25, 26], but it should be noted that this
evidence comes from relatively small cross-sectional
studies and that conclusions on causality cannot be drawn.
Concerning the hypothesis of an anti-arrhythmic effect of
n-3 fatty acids, there was some evidence for protection
against ventricular premature beats [22•], but no evidence
for a relation with heart rate [27] or incidence of atrial
fibrillation [34••]. Moreover, data from two recent well-
conducted epidemiologic studies suggested that high tissue
ALA is related to an increased rather than decreased risk of
fatal cardiovascular events [32] and sudden death [35••].
Harris et al. [36] performed a meta-analysis of previous
studies on tissue fatty acid composition and risk of CHD
published until 2006. They showed that ALA in adipose
tissue or phospholipids was inversely associated with CHD,
although the association was not statistically significant for
fatal events [36]. Of 16 studies reviewed, about half were
supportive for a beneficial role of ALA, whereas other studies
were negative or supportive for an adverse effect [36].
In conclusion, there is a need for long-term trials
investigating the effect of ALA supplementation on
cardiovascular risk factors and clinical end points. Data
are awaited from the Alpha Omega Trial, in which 4,837
post-MI patients (mean age of 69 years) were randomized
to 2 g/d of ALA and/or 400 mg/d of EPA and DHA and
followed for fatal and nonfatal cardiovascular disease
events for 40 months [37]. The findings of this study may
answer the question of whether a food-based dose of ALA
affects cardiovascular health in high-risk individuals and, if
so, whether this is comparable to the effect of marine n-3
fatty acids.
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